Prelude Therapeutics Incorporated
PRLD
NASDAQ·Healthcare·Biotechnology·Mkt cap $310.9M
$5.46
▲ +4.00%
P/E
-20.22
Mkt Cap
$310.9M
52-Wk Range
$0.98–$6.83
52-Week Range
$0.98 - $6.83
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 336.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Average volatility.
Growth
Strong growth ahead
Value
Deep value opportunity - significant discount to sector peers
Momentum
Hot
+43.3% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying PRLD right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 11, 2026
Reported EPS of -$0.14 vs -$0.20 consensus (+28.8% surprise). Revenue of $5.7M vs $5.7M expected (0.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+28.8%
Revenue trend · last 2Q
—
—
Q1 26
Q2 26
$4.6M
$5.7M
Margins · last 2Q
Gross
100.0%
Profit
-244.1%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Jul 15, 2026
vs Industry
How PRLD stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.